



REVOLUTIONIZING FUNCTIONAL BRAIN IMAGING

NeuroLF





Schweizerische Eidgenossenschaft Confédération suisse Confederazione Svizzera Confederaziun svizra

Swiss Confederation

Innosuisse – Swiss Innovation Agency



Co-funded by the Horizon 2020 programme of the European Union



POSITRIGO Facts

- Founded in 2018 by two physicists (Dr. Jannis Fischer, CEO and Dr. Max Ahnen, COO)
- •ETH ZurichSpin Off
- •Award-winning company (Innosuisse R&D grant, Venture Leader, EIC Accelerator)
- •Successful funding rounds
- First product is a brain PET device called NeuroLF[°]
- •CE-mark and FDA clearance expected for beginning of 2024




Headquarter in Technopark Zürich, Switzerland

The Problem

Positron Emission Tomography (PET) is a functional imaging method, which is significantly more sensitive than fMRI and thus extremly valuable in diagnosing diseases like Alzheimer's, Parkinsons, Primary Brain Tumors, Traumatic Brain Injury, and Ischemic Stroke.

Current solutions are inefficient because they are:

- Costly (EUR 2 to 10M)
- Large and heavy (need construction for room)
- Complex to use (multi-operator)
- Overused (long waiting time to access)



The Unmet Need

- The EANM Neuroimaging Committee believes that amyloid PET is at a historical turning point, where it has paved the way for early AD diagnosis and now may also have therapeutic implications.
- In a recent editorial it was noted that approval of disease-modifying treatments for (AD) could increase the need for amyloid PET by a factor of 20.

targets protofibrils, a species of soluble aggregated anyloid- top beta (Aβ). The drug was approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer's sai disease (AD) on January 6, 2023. This approval was based on results of a phase 2 clinical trial [1] and followed the pub- lication of results of a phase 3 trial in November 2022 [2]. The latter study included 1795 patients with early AD, i.e., mild cognitive impairment and mild dementia due to AD. sh This was the first Aβ immunotherapy study to report signifi- cant slowing of progression on the clinical dementia rating scale-sum of boxes at 18 months in the whole cohort, with a mean change from baseline between patients treated with A lecanema by. placebo of $-0.45 (p < 0.001)$ [2]. Moreover, The authors Antoine Verger and Igor Yakushev contributed equality the twe work.	sub-cohort of 698 patients, reduction in amyloid i detected by PET in the lecanemab arm but no cebo arm. An extension study of the long-term e ty, and tolerability of lecanemab is ongoing, with y of a subcutaneous administration of lecanemai nitored exclusively by amyloid PET. Lecanemab is the second PED-approved anti-A r aducanumab [3]. Like lecanemab, aducanum wn to reduce amyloid burden on PET. However, e clinical benefit of aducanumab was mixed, witi cant slowing of cognitive decline only being sh of two identically designed phase 3 clinical tri ucanumab has therefore been not indicated for in the USA and not approved in Europe. A pha y (ENVISION) is ongoing to verify the clinical uducanumab in early AD. Different from aduca- evidence for efficiency of lecanemab has been of across studies and outcomes [1, 2, 4]. The ber Instinute of Nuclear Medicine, University College Londor (UCL), London, UK
targets protofibrils, a species of soluble aggregated anyloid- beta (Aβ). The drug was approved by the U.S. Food and Drug Administration (FDA) for the reatment of Alzheimer's sait disease (AD) on January 6, 2023. This approval was based on results of a phase 2 clinical trial [1] and followed the pub- lication of results of a phase 2 trial in November 2022 [2]. The latter study included 1795 patients with early AD, i.e., mild cognitive impairment and mild dementia due to AD. sh This was the first Aβ immunotherapy study to report signifi- cant slowing of progression on the clinical dementia rating scale-sum of boxes at 18 months in the whole cohort, with eacnemab vs. placebo of −0.45 (<i>p</i> < 0.001) [2]. Moreover, us a the authors Anteine Verger and Igor Yakushev contributed equally the work. This article is part of the Topical Collection on Neurology [2] Igor Yakushev igor yakushev @turn.de 1 Department of Nuclear Medicine, and Nancyclotep Imaging Platform, Université of Lorano, CHRU; LIADI, INSERM U1254, Nancy, France 2 Department of Nuclear Medicine, and Nancyclotep Imaging Platform, Université of Lorano, CHRU; LIADI, INSERM U1254, Nancy, France 2 Department of Nuclear Medicine, Ladwig Maximilians, University of Munich, Mennanger Str. 22, 81675 Manich, Germany 4 Department of Nuclear Medicine, Ladwig Maximilians, University of Munich, Mennanger Str. 22, 81675 Manich, Germany 4 Department of Nuclear Medicine, Ladwig Maximilians, University of Munich, Mennanger Str. 23, 81675 Manich, Germany 4 Department of Nuclear Medicine, Ladwig Maximilians, University of Munich, Mennanger Str. 24, 81675 Manich, Germany 4 Department of Nuclear Medicine, Ladwig Maximilians, University of Munich, Mennanger Str. 24, 81675 Manich, Germany 4 Department of Nuclear Medicine, Ladwig Maximilians, University of Munich, Mennanger Str. 24, 81675 Manich, Germany 4 Department of Nuclear Medicine, Ladwig Maximilians, University of Munich, Mennanger Str. 24, 81675 Manich, Germany 4 Department of Nuclear Medicine, Ladwig	detected by PET in the lecanemab arm but no ceebo arm. An extension study of the long-term ty, and tolerability of lecanemab is ongoing, will y of a subcutaneous administration of lecanema incred exclusively by anyloid PET. Lecanemab is the second FDA-approved anti-A ar aducanumab [3]. Like lecanemab, aducanum wn to reduce amyloid burden on PET. However, et clinical benefit of aducanumab was mixed, wit cant slowing of cognitive decline only being sh of two identically designed phase 3 clinical tri acanumab has therefore been not indicated for in the USA and not approved in Europe. A pha by (ENVISION) is ongoing to verify the clinical ducanumab in early AD. Different from aduca across studies and outcomes [1, 2, 4]. The be Institute of Nuclear Medicine, University College London
The annot Autome Verger and got Taksner Controlled equary to the work. the This article is part of the Topical Collection on Neurology en Igot Yakushev 7 igot yakushev@tum.de 7 Department of Nuclear Medicine and Nancyclotep Imaging Platform, Université de Lorraine, CHRU; LADI, INSEEM U1254, Nancy, France 9 Porpartment of Nuclear Medicine, School of Medicine, Technical University of Munich, Ismaninger Str. 22, 81675 Munich, Germany 10 Department of Nuclear Medicine, Ladwig Maximilians University of Munich, Munich, Germany 11 Department of Ruiclear Medicine, Ludwig Maximilians University Medical Center Utrecht, Utrecht, the Netherlands 12	evidence for efficiency of lecanemab has been of across studies and outcomes [1, 2, 4]. The ber Institute of Nuclear Medicine, University College Londor
Igor Yakushev 7 igor yakushev @tum.de 7 1 Department of Nuclear Medicine and Nancyclotep Imaging Platform, Université de Lornine, CHRU; IADI, INSERM U1254, Nancy, France 8 2 Department of Nuclear Medicine, School of Medicine, Tecchnical University of Munich, Ismaninger Str. 22, 81675 Munich, Germany 19 3 Department of Nuclear Medicine, Ladwig Maximilians-University of Munich, Mennich, Germany 19 4 Department of Nuclear Medicine, Netherinads 11 4 Department of Urecht, the Netherlands 12	
¹ Department of Nuclear Medicine and Nancyclotep Imaging Platform, Université de Lorraine, CHRU; LIADI, INSERM U1254, Nancy, France 9 ² Department of Nuclear Medicine, School of Medicine, Technical University of Munich, Ismaninger Str. 22, 81675 Manich, Germany 10 ³ Department of Nuclear Medicine, Ludwig Maximilians-University of Munich, Manich, Germany 11 ⁴ Department of Radiology and Nuclear Medicine, University Medical Center Unceht, Utrecht, the Netherlands 12	
² Department of Nuclear Medicine, School of Medicine, Technical University of Munich, Ismaninger Str. 22, 81675 Munich, Germany 10 ³ Department of Nuclear Medicine, Ludwig Maximilians-University of Munich, Munich, Germany 11 ⁴ Department of Ruclear Medicine, University Medical Center Utrecht, Utrecht, the Netherlands 12	APHM, CNRS, Centrale Marseille, Nuclear Medicine Department, Institut Fresnel, Timone Hospital, CERIMEI Aix Marseille Univ, Marseille, France
81675 Munich, Germany 10 3 Department of Nuclear Medicine, Ladwig Maximilians-University of Munich, Munich, Germany 11 4 Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Utrecht, the Netherlands 12	Nuclear Medicine Unit, Department of Health Sciences, University of Genoa, Genoa, Italy
Maximilians-University of Munich, Munich, Germany ¹¹ ⁴ Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Utrecht, the Netherlands ¹²	Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, Groningen, the Netherlands
12	Division of Nuclear Medicine, Department of Biomedica Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria
University of Padua, Padua, Italy	Department of Radiology and Nuclear Medicine, Ghent University Hospital, Ghent, Belgium
¹³ Department of Radiology, Faculty of Medicine and Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), University of Stantiago de Compostela (USC), Campus Vida, Santiago de Compostela, Galicia, Spain	Department of Nuclear Medicine, Leipzig University, Leipzig, Germany
	ව
0	

Check for

European Journal of Nuclear Medicine and Molecular Imaging (2023) 50:1553-1555

https://doi.org/10.1007/s00259-023-06177-5

EDITORIAL

Verger et al., 2023

Meet NeuroLF $^{\circ}$

- NeuroLF[®] is a brain PET scanner specifically designed for the diagnosis of brain related disorders
- Ultra-compact design
- Attractive price value proposition
- High patient comfort
- Intuitive Usability



Scan QR-code to watch **NeuroLF**® video



Ultra-Compact





NeuroLF[®] Benefits

Benefits for Clinicians

- Lower investment cost
- Small footprint
- Intuitive Usability
- Dedicated brain PET including sophisticated imaging reconstruction
- Easier patient handling resulting in increased throughput



NeuroLF[®] Benefits

Benefits for Patients

- Cost efficient access to dedicated brain related disease diagnosis
- Fast intervention
- Comfortable procedure
- Allows for differential diagnosis and therefore more specific information for patients



"For centers with an increasing need to efficiently diagnose brain disorders, NeuroLF[®] offers state-of-the-art functional brain imaging at a fraction of today's overall cost."



Prof. em. Alfred Buck Former Director of NeuroPET Program at University Hospital of Zurich, Switzerland

NeuroLF[®] Applications



Dementia Alzheimer's disease Neuro-Oncology Gliomas Epilepsy

Movement Disorders Parkinson's disease

Positrigo Management & Board



Dr. Jannis Fischer CEO & Co-Founder Alumni of ETH Zurich, FU & HU Berlin, and UCLA. 8+ years experience in PET system development. Forbes 30 under 30 listed.



Dr. Max Ahnen COO & Co-Founder & Board Member Alumni ofETH Zurich, FU & HU Berlin, and UCLA. 8+ years experience in detector development. Forbes 30 under30 listed.



Chief Commercial Officer 20+ years' experience in robotics and health care technologies in the areas of product management, general management and sales & marketing with focus of go-to-market activities for international operations.

Dr. Ilaria Sacco

Dr. Stefan Bircher

Chief Technology Officer Decade of experience in designing electronics hardware and sensors readout circuits for medical imaging instrumentation, robotics surgical devices and particle detectors.









Urs Suter, Chairman of the Board Former CEO and chairman of the board of directors at Siemens Healthcare AG and Healthcare Diagnostics GmbH.

Prof. em. Dr. Alfred Buck, Board Member Co-Founder of Swisstrace and former Professor and Head of NeuroPET at the University Hospital Zurich. Buck helps the team build a device from clinicians, for clinicians.

Dr. Jean-Pierre Rosat, Board Member Serial entreprenuer, PhD in Immunology, Post-doc at Harvard Medical School. long experience in entrepreneurship(co-founded and managed over 12 Swiss start-ups). General partner and Founder at 4FO Venture Partners.

Alexander Vamvakas, Board Member

Alex is involved in private equity and venture capital investments at Fairway Asset Management AG. He is passionate about technology and innovation, and he holds a diploma from the National Technical University of Athens and an MSc from Imperial College London.





Thank you!

info@promedeuslab.cz promedeuslab.cz